Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Clin Pharmacol Ther ; 83(1): 167-71, 2008 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-18000515

RESUMEN

Systemic lupus erythematosus (SLE) is a prototypic inflammatory autoimmune disorder characterized by multisystem involvement and fluctuating disease activity. Symptoms range from rather mild manifestations such as rash or arthritis to life-threatening end-organ manifestations such as glomerulonephritis or thrombosis. Virtually every organ system is subject to potential damage. Symptoms typically wax and wane over the course of the disease; yet unfortunately, many patients will experience a slow decline in their health because of the ongoing systemic inflammation. Effective treatment must be individualized and is often based on the specific manifestations that are seen in each patient. In a similar manner, prognosis is also dependent on the severity and the specific organ systems involved.


Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Terapia Biológica/tendencias , Inmunosupresores/uso terapéutico , Lupus Eritematoso Sistémico/tratamiento farmacológico , Anticuerpos Monoclonales/efectos adversos , Antígenos CD/inmunología , Antígenos CD20/inmunología , Antígenos de Diferenciación/inmunología , Factor Activador de Células B/antagonistas & inhibidores , Factor Activador de Células B/inmunología , Antígeno CD11a/inmunología , Ligando de CD40/antagonistas & inhibidores , Ligando de CD40/inmunología , Antígeno CTLA-4 , Humanos , Inmunosupresores/efectos adversos , Lupus Eritematoso Sistémico/inmunología , Selección de Paciente , Pronóstico , Lectina 2 Similar a Ig de Unión al Ácido Siálico/inmunología , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Factor de Necrosis Tumoral alfa/inmunología
2.
Nutrition ; 22(4): 408-13, 2006 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-16458482

RESUMEN

OBJECTIVES: This study investigated the effects of glutamine (Gln) on plasma intracellular adhesion molecule-1 levels and leukocyte integrin (CD11a/CD18 and CD11b/CD18) expressions in gut-derived sepsis. Myeloperoxidase (MPO) activities in organs were also analyzed to identify the extent of tissue injury resulting from neutrophil infiltration. METHODS: Mice were randomly assigned to a normal group (NC), a control group, or a Gln group. The NC group was fed standard chow diet; the control group was fed a common semipurified diet; and the Gln group received a diet in which part of the casein was replaced by Gln, which provided 25% of total amino acid nitrogen. After 3 wk, sepsis was induced by cecal ligation and puncture (CLP) in the control and Gln groups. Mice in the experimental groups were killed at 0, 6, 12, and 24 h after CLP. Mice in the NC group were killed when CLP was performed. Blood and organ samples were collected for further analysis. RESULTS: Plasma intracellular adhesion molecule-1 levels were significantly lower in the Gln group than in the control group at 6, 12, and 24 h after CLP. Expressions of lymphocyte CD11a/CD18 were significantly higher, whereas polymorphonuclear lymphocyte expressions of CD11b/CD18 were lower in the Gln group than in the corresponding control group at 6 and 12 h after CLP. In comparisons of MPO activities in various organs, the Gln group had lower MPO activities at 6 and 12 h in the lung, at 6, 12, and 24 h in the liver, at 12 and 24 h in the kidneys, and at 12 h in the intestine than those in the control group. CONCLUSIONS: Results of this study demonstrate that a Gln-supplemented enteral diet increased lymphocyte CD11a/CD18 expressions, whereas neutrophil CD11b/CD18 expressions, circulating intracellular adhesion molecule-1 levels, and MPO activities in various organs decreased with gut-derived sepsis. These findings suggest that, under septic conditions, Gln administration may enhance lymphocyte function, attenuate interactions between polymorphonuclear lymphocytes and endothelium, and thus may decrease neutrophil infiltration into tissues.


Asunto(s)
Regulación de la Expresión Génica/efectos de los fármacos , Glutamina/uso terapéutico , Molécula 1 de Adhesión Intercelular/metabolismo , Peroxidasa/metabolismo , Sepsis/inmunología , Animales , Antígeno CD11a/efectos de los fármacos , Antígeno CD11a/inmunología , Antígeno CD11a/metabolismo , Antígeno CD11b/efectos de los fármacos , Antígeno CD11b/inmunología , Antígeno CD11b/metabolismo , Antígenos CD18/efectos de los fármacos , Antígenos CD18/inmunología , Antígenos CD18/metabolismo , Suplementos Dietéticos , Regulación de la Expresión Génica/inmunología , Glutamina/administración & dosificación , Masculino , Ratones , Ratones Endogámicos ICR , Infiltración Neutrófila , Distribución Aleatoria , Sepsis/metabolismo
3.
Eur J Dermatol ; 16(6): 623-35, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-17229602

RESUMEN

CD11a-blocking efalizumab has recently been approved as a systemic treatment of moderate to severe chronic plaque psoriasis. When treating 6 psoriasis patients with efalizumab over 12 weeks in the present study, we observed an overall good tolerability and 5 treatment responders characterized by a decrease of PASI from 21.3 +/- 5.4 to 3.9 +/- 0.6. The accompanying significant increase of peripheral blood lymphocytes from 1.9 +/- 0.7 to 4.3 +/- 1.0 x 10(9)/L (p < 0.05) was analyzed by multi epitope ligand cartography (MELC) robot microscopy. Thereby a high-dimension simultaneous multiplex immunophenotyping was pursued using 39 fluorophore-labeled antibodies including labeled efalizumab and 3 other affinity reagents such as lectins. Due to efalizumab treatment there was a substantial decrease of the cellular expression of CD11a (detected by mab clone 25.3.1) and efalizumab binding sites (EfaBSs). This was paralleled by an increase of the number of EfaBS- and EfaBS+ lymphocytes by a factor of 2.4x and 2.2x, respectively. The latter effect was mainly derived from a subpopulation showing a low degree of EfaBS expression. Efalizumab treatment led furthermore to an increase of the numbers of CD3+, CD4+, CD8+, CD44+, CD45+, CD45R0+, CD45 RA+, CD52+, CD58+, CD247+, HLA-DR+ and Sambucus nigra lectin-reactive lymphocytes (by factors from 2.0 to 3.3x). In terms of a combinatorial molecular phenotype we identified a CD3+/CD4+/CD44+/CD52+ lymphocyte subpopulation which accumulated most predominantly from 0.824 +/- 0.270 x 10(9)/L up to 1.616 +/- 0.152 x 10(9)/L under efalizumab treatment (p < 0.01). Thus, the current study extends the knowledge of efalizumab-dependent perturbations of recirculating blood lymphocyte subpopulations in psoriasis patients.


Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Antígeno CD11a/inmunología , Subgrupos Linfocitarios/inmunología , Psoriasis/tratamiento farmacológico , Psoriasis/inmunología , Adulto , Anticuerpos Monoclonales/farmacocinética , Anticuerpos Monoclonales Humanizados , Antígenos CD/sangre , Sitios de Unión , Antígenos CD11/inmunología , Epítopos/análisis , Humanos , Recuento de Leucocitos , Ligandos , Robótica , Resultado del Tratamiento
4.
Regul Toxicol Pharmacol ; 40(3): 219-26, 2004 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-15546677

RESUMEN

Surrogate antibodies are a potential solution to the limited safety testing possible with humanized monoclonal antibodies with restricted species cross-reactivity. However, there are currently no defined criteria by which a potential surrogate antibody should be judged prior to its use in determining safety issues for the clinical agent. We propose that, potential surrogates should undergo rigorous evaluation to assess pharmacological and toxicological activities in comparison to the clinical agent. The current studies evaluated a chimeric mouse/rat anti-mouse CD11a monoclonal antibody (muM17) as a potential surrogate for efalizumab, a humanized anti-CD11a antibody in development for psoriasis. CD11a is a subunit of lymphocyte function associated antigen-1, an integrin involved in cell-cell interactions important to immune responses and inflammation. In vitro pharmacology studies included binding affinity to whole mouse blood and inhibitory activity of muM17 in a mixed lymphocyte response assay. In vivo pharmacology was examined using a delayed type hypersensitivity assay in female CD-1 mice. The toxicology evaluation included a murine tissue cross-reactivity study and in vivo multiple dose studies in female CD-1 mice which were administered muM17 (0.1-30 mg/kg) via subcutaneous injections once a week for 4 weeks. Clinical observations, body weight, clinical pathology, T cell CD11a expression, immunogenicity, toxicokinetics, and lymphoid organ histopathology were evaluated. Finally, since reproductive safety testing would be an important application of the proposed surrogate antibody, a pilot study in pregnant mice was conducted that demonstrated proportional transfer of muM17 into the fetus. These studies demonstrated that muM17 has pharmacological and toxicological activities similar to efalizumab. The selection of dose and regimen for GLP (Good Laboratory Practice) toxicology studies and extrapolation to clinical dose levels was based on pharmacodynamic activity (CD11a downmodulation on T cells).


Asunto(s)
Anticuerpos Monoclonales/toxicidad , Antígeno CD11a/inmunología , Animales , Anticuerpos Monoclonales Humanizados , Antineoplásicos/toxicidad , Reacciones Cruzadas , Evaluación Preclínica de Medicamentos , Ensayo de Inmunoadsorción Enzimática , Femenino , Citometría de Flujo , Humanos , Hipersensibilidad Tardía/patología , Inmunoglobulina G/inmunología , Técnicas In Vitro , Recuento de Leucocitos , Prueba de Cultivo Mixto de Linfocitos , Masculino , Ratones , Ratas , Reproducción/efectos de los fármacos , Linfocitos T/efectos de los fármacos , Linfocitos T/inmunología
5.
Arthritis Rheum ; 50(10): 3377-86, 2004 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-15476252

RESUMEN

OBJECTIVE: Ex vivo and in vivo micro-computed tomography (micro-CT) combined with a novel image analysis algorithm were used to quantify cortical bone loss and periosteal new bone formation for therapeutic evaluation in a murine model of collagen-induced arthritis. METHODS: An automated algorithm was created to locate 5 metatarsophalangeal and 3 metacarpophalangeal joints in 3-dimensional micro-CT images of mouse paws for evaluation of joint cortical bone volume (JCBV) within close proximity of the joints as well as cortical bone mineral density and periosteal new bone formation within the paws. For validation, automated estimates of JCBV were compared with radiographic visual scores (RVS) in 4 treatment groups (n = 9 per group): rat anti-mouse CD11a monoclonal antibody, methotrexate (MTX), anti-CD11a plus MTX, and saline only. In a separate study, serial images of hind limbs were evaluated in 2 treatment groups: murine tumor necrosis factor receptor II-Fc fusion protein (mTNFRII; n = 10) and control antibody (n = 7). RESULTS: Automated estimates of the JCBV were significantly correlated with the RVS (hind paws R = -0.94, front paws R = -0.81, combined R = -0.87). The anti-CD11a group had significantly higher JCBV compared with controls. In the serial study, the automated estimate of JCBV detected significant treatment effects in the mTNFRII-Fc group compared with controls. Cortical bone mineral density was significantly higher in all treatment groups compared with controls. CONCLUSION: Micro-CT combined with a novel image analysis technique (estimation of JCBV) provides a fully automated means to quantify bone destruction in a mouse model of rheumatoid arthritis.


Asunto(s)
Artritis Experimental/diagnóstico por imagen , Artritis Experimental/terapia , Artritis Reumatoide/diagnóstico por imagen , Artritis Reumatoide/terapia , Densidad Ósea , Osteogénesis , Tomografía Computarizada por Rayos X/métodos , Algoritmos , Animales , Artritis Experimental/inducido químicamente , Artritis Experimental/patología , Artritis Reumatoide/inducido químicamente , Artritis Reumatoide/patología , Autoanticuerpos/uso terapéutico , Antígeno CD11a/administración & dosificación , Antígeno CD11a/inmunología , Colágeno , Masculino , Metotrexato/administración & dosificación , Metotrexato/uso terapéutico , Ratones , Ratones Endogámicos DBA
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA